Komori
KYORIN Pharmaceutical (4569) · PolicyRestated

Adoption of Accounting Standards for Revenue Recognition

First written in FY2022-Q1. 2 of 3 entries say "Restated". Latest entry: FY2022-Q3.

3entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2022-Q1 – FY2022-Q32021: 220212022: 12022
Same theme, other companies

The whole theme swung hardest in 2025: 2 of 9 companies on the "Worse" side.

48 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 82 companies compared. The sentences above are computed from all 82.
Full recordFilings, disclosures and news, newest first
  1. FY2022-Q3RestatedAnnual report

    「As a result, net sales for the cumulative third-quarter period decreased by ¥816 million and selling, general and administrative expenses decreased by ¥816 million, but there was no change in operating profit, ordinary profit or quarterly profit before income taxes and other adjustments.」

    The company continues to apply the Accounting Standard for Revenue Recognition, resulting in net sales and selling, general and administrative expenses each decreasing by ¥816 million, with no impact on profit.
  2. FY2022-Q2RestatedAnnual report

    「As a result, net sales for the cumulative second-quarter period decreased by ¥611 million and selling, general and administrative expenses decreased by ¥611 million, but there was no change in operating loss, ordinary profit or quarterly profit before income taxes and other adjustments.」

    The company continues to apply the Accounting Standard for Revenue Recognition, resulting in net sales and selling, general and administrative expenses each decreasing by ¥611 million, with no impact on profit.
  3. FY2022-Q1First statedAnnual report

    「From the beginning of the first quarter of the consolidated fiscal year, we applied the Accounting Standard for Revenue Recognition and related standards and recognize revenue at the amount expected to be received in exchange for the goods or services when the customer obtains control of the promised goods or services.」

    The revenue recognition standard was applied from 1 April 2021, changing the treatment of certain sales incentives so that they reduce the transaction price. Revenue and SG&A each decreased by ¥256 million, with no impact on operating loss or other profit figures.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for KYORIN Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Adoption of Accounting Standards for Revenue Recognition | KYORIN Pharmaceutical Co.,Ltd. (4569) | Komori